⚠️ Teaching Case Note: This case has been de-identified and reconstructed for educational purposes. Clinical details reflect real surgical decision-making and outcomes. Patient identity is fully protected.
Early Esophageal Cancer, Removed Without Surgery — Three Years Later, Still Clear
He had been ignoring the sensation for three months. A 68-year-old man — forty years of drinking, thirty of smoking — noticed food catching slightly as he swallowed. He adapted, ate more carefully, and kept going. Then it worsened. One week of progressive dysphagia brought him to endoscopy.
What the scope found was a 3.0×2.5 cm lesion in the mid-esophagus, 30 cm from the incisors: irregular surface, erosion, a Ⅱb+Ⅱc morphology under white light. Narrow-band imaging with magnification showed IPCL pattern B3 — the vascular signature of early cancer. Biopsy confirmed high-grade intraepithelial neoplasia with focal suspicious microinvasion. EUS and CT excluded lymph node involvement and deep wall infiltration: T1a, N0.
The lesion was too large for conventional endoscopic mucosal resection. Surgery — esophagectomy — was the standard alternative. Dr. Ping-Hong Zhou's team at Zhongshan Hospital offered a third option: endoscopic submucosal dissection (ESD), performed in a single session, removing the lesion en bloc with clear margins and no incision.
Three years later, the patient has no evidence of recurrence and a quality of life score of 90 out of 100.
The Diagnosis: Early Cancer, High Technical Difficulty
The endoscopic workup was thorough. White-light endoscopy identified the lesion morphology — Ⅱb (flat) combined with Ⅱc (slightly depressed) — at the mid-esophagus. NBI magnification characterized the intrapapillary capillary loop (IPCL) pattern as B3: irregular, dilated, tortuous vessels indicating high-grade dysplasia or early invasive cancer. Chromoendoscopy with Lugol's iodine confirmed the lesion boundaries as a sharply demarcated unstained zone.
EUS measured the lesion depth at T1a — confined to the mucosal layer, with no submucosal invasion and no suspicious lymph nodes. Chest CT confirmed N0 status. The staging picture was clear: early esophageal squamous cell carcinoma, potentially curable by endoscopic resection alone.
Three factors elevated the technical difficulty. The lesion diameter exceeded 3 cm — the threshold above which conventional EMR cannot achieve en bloc resection and piecemeal removal risks positive margins and local recurrence. Forty years of alcohol and tobacco exposure raised the probability of submucosal fibrosis, which hardens the tissue plane that ESD must navigate and increases perforation risk. And the mid-esophageal location demanded preservation of swallowing function — post-procedural stricture was a real risk for a circumferential or near-circumferential resection of this size.
The multidisciplinary team — gastroenterology, thoracic surgery, oncology, and nutrition — reviewed the case. ESD was selected as the primary approach, with prophylactic balloon dilatation planned intraoperatively to reduce stricture risk.
The Procedure: En Bloc Resection in Five Phases
Phase 1 — Marking. Using a DualKnife (Olympus), electrocautery marking dots were placed 5 mm outside the lesion boundary in all directions — confirmed under NBI and Lugol's chromoendoscopy. The margin was deliberately generous: in squamous cell carcinoma, the lateral extent of dysplastic change can extend beyond the visible lesion edge.
Phase 2 — Submucosal injection. A mixed solution of glycerol fructose (for sustained mucosal lifting), indigo carmine (for tissue plane visualization), and epinephrine 1:100,000 (for hemostasis) was injected into the submucosal layer beneath the lesion. Adequate lifting confirmed that the lesion had not invaded the submucosal layer — a real-time safety check. The blue-stained submucosal cushion created the working space for dissection.
Phase 3 — Mucosal incision. Circumferential incision was made along the outer edge of the marking dots, entering the submucosal layer and establishing the dissection plane around the full lesion perimeter.
Phase 4 — Submucosal dissection. An ITknife2 (Olympus) — selected for its ceramic-coated insulated tip and short blade geometry, which improve cutting efficiency in fibrotic tissue while reducing the risk of inadvertent muscle layer injury — was used to dissect the submucosal layer systematically. A transparent cap (Olympus D-201-11802) mounted on the endoscope tip provided mechanical countertraction, improving visualization of the dissection plane. Where submucosal fibrosis was encountered, a tunnel dissection strategy was applied: normal tissue was separated first to establish a safe plane, then the approach advanced progressively into the fibrotic zone — reducing the risk of disorientation and perforation in the most technically demanding segments. Muscle layer color (grey-white) was monitored continuously as a depth indicator.
Phase 5 — Wound management and prophylactic dilatation. After en bloc specimen retrieval, the resection wound was treated with Coagrasper (Olympus) electrocoagulation for hemostasis and fibrin glue (Tisseel, Baxter) spray to promote mucosal healing. A 12 mm balloon dilatation catheter (Boston Scientific) was then placed at the resection site and inflated to 10–12 psi for one minute — a prophylactic measure to reduce the risk of post-ESD esophageal stricture, which is the primary functional complication of large esophageal resections.
Pathology: Complete Resection, Clear Margins
The en bloc specimen measured 4.0×3.5 cm — larger than the endoscopic estimate, as expected after submucosal injection and tissue relaxation. Final pathology: esophageal squamous cell carcinoma, pT1a-MM (muscularis mucosae invasion). Both horizontal and vertical resection margins were negative. No lymphovascular invasion. No perineural invasion.
The pathological staging confirmed curative resection: T1a-MM with negative margins carries a lymph node metastasis risk below 5% in the absence of lymphovascular invasion, making endoscopic resection alone an accepted curative treatment without adjuvant therapy.
Recovery and Three-Year Follow-Up
The post-procedural course was uncomplicated. No chest pain, no fever, no signs of perforation or delayed bleeding. Liquid diet resumed at 48 hours. Discharge at one week.
The follow-up trajectory was equally clean. At three months, endoscopy showed well-healed mucosa with no stricture — esophageal diameter maintained above 12 mm, the functional threshold for normal swallowing. At one year, EUS and PET-CT confirmed no local recurrence and no distant metastasis. Swallowing was normal; the dysphagia that had brought him to endoscopy was gone.
At three years: no tumor recurrence. EORTC QLQ-C30 quality of life score: 90 out of 100.
His own words: "I came in thinking I might need major surgery. I left a week later with no scar, no tube, no chemotherapy. Three years on, I eat normally, I feel normal. I tell everyone I know to get their endoscopy done early."
Why ESD — and Why Early Detection Changes Everything
The curative potential of ESD in early esophageal cancer depends entirely on stage. T1a disease — confined to the mucosal layer — carries a lymph node metastasis risk below 5%. T1b disease — submucosal invasion — carries a risk of 20–50%, requiring surgical resection or combined modality treatment. The difference between these two stages is measured in millimeters of tissue depth. EUS and NBI magnification make that distinction possible before any treatment decision is made.
For lesions above 2 cm, EMR cannot achieve en bloc resection — piecemeal removal fragments the specimen, making margin assessment unreliable and local recurrence rates substantially higher (30–50% versus under 5% for ESD). ESD's ability to remove any size lesion as a single piece is its defining oncological advantage.
Post-ESD stricture — the main functional risk — occurs in 30–50% of cases after conventional EMR for large lesions. With prophylactic intraoperative balloon dilatation and structured follow-up, that rate can be reduced to below 10%. This patient had none.
The long-term surveillance protocol for this patient reflects the elevated second primary cancer risk in heavy smokers and drinkers: esophageal cancer patients face a 2–3-fold increased risk of synchronous or metachronous head and neck or gastric malignancy. Endoscopy every 3–6 months for the first two years, then annually, is not optional — it is the standard of care.
Expert Commentary — Dr. Ping-Hong Zhou
"ESD is not a simpler version of surgery. It is a different discipline — one that requires mastery of endoscopic anatomy, tissue mechanics, and real-time decision-making under conditions that change with every millimeter of dissection.
This case had three compounding difficulties: lesion size above 3 cm, probable submucosal fibrosis from decades of alcohol exposure, and a mid-esophageal location where stricture risk is highest. Each of these, individually, would make many endoscopists refer to surgery. Together, they require a structured technical response: the right injection mixture for sustained lifting, the right knife geometry for fibrotic tissue, the tunnel strategy for navigating the difficult zone, and prophylactic dilatation before the wound even closes.
The three-year outcome — no recurrence, no stricture, quality of life at 90 — is what early detection and precise technique can deliver. The same lesion found one year later, with submucosal invasion, would have required esophagectomy. That is the argument for screening in high-risk populations. Find it early. Remove it completely. Follow it carefully."
About Dr. Ping-Hong Zhou
Dr. Ping-Hong Zhou is Chief of Endoscopy at Zhongshan Hospital, Fudan University, internationally recognized for his expertise in endoscopic submucosal dissection (ESD) and early gastrointestinal cancer detection. He has trained endoscopists across Asia and Europe and holds multiple world records in ESD procedure volume. Dr. Zhou is a go-to specialist for complex GI lesions requiring non-surgical removal, with particular expertise in large esophageal, gastric, and colorectal ESD, submucosal tunnel endoscopy (STER/POEM), and endoscopic full-thickness resection (EFTR).
How CMCS Supported This Patient
China Medical Concierge – Shanghai (CMCS) coordinated the full care pathway: case review and specialist matching at Zhongshan Hospital Fudan University, pre-procedural EUS and NBI endoscopy scheduling, on-site Mandarin-English interpretation for all consultations and procedural consent discussions — including the detailed informed consent process for a high-complexity ESD in a high-risk anatomical location — accommodation near the hospital during the one-week admission, and long-term follow-up coordination including three-monthly endoscopy scheduling for the first two years, annual PET-CT and EUS review, and dietary and smoking cessation support referral.
For international patients and expatriates in Shanghai facing early GI cancer diagnosis or complex endoscopic lesions — where the difference between endoscopic cure and major surgery depends on specialist access and precise staging — CMCS provides end-to-end support from first endoscopy to long-term surveillance.
📧 contract@medicalsh.com | 📱 WhatsApp | 🌐 medicalsh.com
0 comentarios